Carfilzomib and irinotecan in relapsed small cell lung cancer

Dr Susanne Arnold talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase II study looking into Carfilzomib and irinotecan in relapsed small cell lung cancer.

She explains that there were two cohorts: platinum sensitive cancers and platinum resistant cancers.

Dr Arnold reports that in both cohorts at 6 months the overall survival was 59% for the platinum sensitive cohort and 54% for the platinum resistant cohort.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.phps